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Foxp3 cells (T ) were quantified. A Th17/T ratio<1 correlated both with the clinical diagnosis (p<0.001), and 2 pathologic

Introduction
Graft versus host disease (GvHD) involves dysregulation of inflammatory cytokine cascades and distorted donor cellular response against host alloantigens (reviewed in ). The characterization of CD4 /interleukin 17 (IL-17)-secreting subset (Th17) and of the 1 + regulatory CD4 /Foxp3 cell (T ) has had a major impact on our understanding of immune processes . Th17 and T might + + reg 2 -6 reg contribute to human autoimmune diseases, including inflammatory bowel disease (IBD) . Experimental data suggest a reciprocal 2 -5 relationship between Th17-induced pathology, and T regulatory role. In murine models, Th17 cells induce autoimmunity through tissue reg inflammation promotion, and innate immune system mobilization . However, in the gut Th17 cells might also have modulatory and 2 -5 protective roles. Murine models provide recent controversial results on the role of Th17 in GvHD ,
. We are not aware of any 4 7 -11 published data on Th17 cells in human GvHD. To investigate their potential implication in GvHD-induced inflammation, we studied Th17 and T in 3 independent cohorts of patients (n 96) who had gut or skin biopsies and their relationship with histological and clinical reg = parameters.
Patients and methods
Patients
Our primary aim was to study Th17 and Treg populations in the setting of gastro-intestinal (GI) GvHD. Biopsies were performed as diagnostic procedures for digestive symptoms. Clinical grading used the 1994 consensus conference criteria and pathological were 12 2 11 performed as previously described . Hospital Saint Louis ethical review board approved the design of this study. Patients with digestive 13 symptoms underwent endoscopy and biopsies before any treatment with steroids. We first took advantage of a first study in which 13 patients biopsies have been extensively studied for Fas, TNF and apoptosis pathways to search for Treg and Th17 infiltration and association with Fas and TNF pathways (if any). Then, we aimed to confirm results of Treg and Th17 localization in an independent cohort of patients with GI GvHD and search for a role (if any) of the intensity of the conditioning regimen. Finally we studied these cell subsets in patient with skin GvHD. Thus, 3 different cohorts of patients (total n 96) were sequentially studied: = 40 out of 78 patients from the previously published cohort had available duodenal biopsies. Median age was 34 years. Conditioning regimens (all myeloablative) included total body irradiation (TBI) and cyclophosphamide (n 13), or associated busulfan (Bu) and = cyclophosphamide (n 15). Acute lymphoblastic leukemia patients received TBI or Bu with melphalan and cytarabine (n 9). Aplastic = = anemia patients received cyclophosphamide and anti-thymocyte globulins. Cyclosporine and methotrexate were used for most patients (n= 28). Patients underwent duodenal biopsies for unexplained nausea or vomiting (n 9) or stage 1 2 diarrhea (n 31).
= -=
A second cohort of 30 patients with GI biopsy was studied to confirm in an independent series biological results in GI-GvHD. It included:
11 patients (4 males, 7 females; median age 30 years) with pathological GI GvHD who underwent an allogeneic SCT after myeloablative conditioning. Ten patients were grafted for hematological malignancies. All had stage 2 clinical lower GI GvHD at the time of biopsy.
10 patients (6males, 4 females; median age 48 years) who underwent SCT after a reduced intensity conditioning that included fludarabine and 2Gy TBI in 6 patients (according to the Seattle s regimen) and low dose IV busulfan fludarabine and ATG in 4 patients ' (according to the MD Anderson s regimen). All 10 patients with hematological malignancies had also biopsy-proven GI GvHD (8 patients ' had stage 1 and 2 patients had stage 2 lower GI GvHD at the time of biopsy).
Finally, 9 patients who had no evidence of pathological GvHD at the time of upper GI biopsy were used as controls in this second cohort. These patients (6 males, 3 females; median age 30 years) underwent SCT for hematological malignancies either after a myeloablative (n 5), or a Fludarabine 2Gy TBI reduced intensity conditioning (n 4) (4 patients had stage 1 lower GI GvHD at the time = + = of biopsy and 5 patients had unexplained nausea/vomiting).
Finally, a 3 cohort of 26 patients with skin rash was studied. This series included 10 patients with biopsy-proven acute GVHD, 5 rd patients with evidence of pathological chronic GvHD and 11 patients without evidence of GvHD after pathological examination of skin biopsies. The 10 patients (7 males, 3 females; median age 34 years) with acute GvHD all underwent SCT for hematological malignancies after a myeloablative conditioning regimen. Four out of the 5 patients with chronic GvHD (3 males, 2 females, median age 43 years) also received a myeloablative conditioning, and all 5 had acute leukemia. Finally among the 11 patients (7 males, 4 females; median age 36 years) without pathological skin GvHD, 9 underwent SCT for malignant diseases and 2 for Fanconi anemia.
Methods
Duodenal biopsies during fiber-optic examination and skin biopsies were performed, as previously described . All biopsies 13 -14 were performed before any steroid treatment, and for GI biopsies two of them used for systematic viral or fungal infection detection.
Histological digestive and skin GVHD grading was done as previously described . 13 TUNEL assay and immunohistochemistry were performed on frozen sections using CD45RA (Dako, Denmark), CD68 (Dako, (clone 22510, Abcam; dilution 1:50), or polyclonal rabbit antibody to IL-17 (H-132 sc-7927, Santa-Cruz; dilution 1:100) were applied to sections for 1 hour at RT. Sections were finally mounted in Vectashield medium containing DAPI. CD4 Th17/CD4 T ratio was reg expressed as median and inter-quartile range (IQR) of the number of cells per field at 400 magnification. × Examiners were aware of clinical signs and treatment (if any) of the patients at the time of biopsies and for routine GvHD pathological evaluation. However, for Th17/Treg stainings patients were identified by anonymous 7 digits code corresponding to laboratory identification. It is thus unlikely that one examiner could associate patient identification with biopsy code. More importantly, biopsies were independently evaluated by 2 examiners (PR and AJ). In all cases of disagreement between examiners, a common reading was organized to achieve a consensus on count. 
Flow cytometry and intracellular cytokine staining
Statistical analyses
Reproducibility of Th17 and T counts was assessed through examination of discrepancy levels between the 2 examiners and The numbers of CD4 expressing IL-17 or Foxp3 was low ( ): CD4 Th17 ranging from 0 to 8 cells per field with a median of + Figure 1 1 (IQR 0.25 4); CD4 T median being 4 (IQR 1 6), with a median Th17/T ratio of ( ). Severe apoptosis, assessed by Table 1A TUNEL, was found in 29 patients, Fas positive mononuclear cells in 23, significant TNF alpha expression in 20 and TNF receptor 1 in 26 ( ). Table 1B In the 34 patients with pathological GvHD, CD4 Th17 cells numbers ranged between 0 and 7 with a median of 1, whereas CD4-T reg ranged between 0 and 11 with a median of 5 ( ). A Th17/T ratio<1 correlated both with the clinical (sensitivity 74 , specificity Table 1A reg % 100 , p 0.001), and pathological grade 2 GvHD (sensitivity 94 , specificity 64 , p<0.001). Apoptotic epithelial cells were associated Table 1B We next wanted to confirm, in an independent cohort (2 cohort), results concerning Th17 and T cells in human GI GvHD and to nd reg search if the intensity of the conditioning regimen (reduced intensity vs. myeloablative) influences the expression ratio of these 2 cell subsets. As summarized in and , we found nearly the same results than in the previously studied cohort regarding Th17 Figure 2 Table 2 and T cell density with regard to GvHD occurrence. However, neither Th17 (p 0. Since recent experimental results in a mouse model suggest that Th17 cells might be more involved in skin GvHD rather than in GI GvHD , , we analyzed data in an additional cohort of 25 patients (3 cohort) with acute skin rash or chronic lichenoid skin lesions 4 7 -11 rd who underwent skin biopsies ( ). As summarized in , we found again similar results regarding Th17 and T cell ratio with Figure 4 Table 3 reg regard to acute GvHD occurrence. Results in chronic GvHD were statistically insignificant with regard to Th17 and T cell numbers but reg showed similar trends with regards to Th17/T . humans . In this first study of Th17 in human GvHD we found a lower number of CD4 Th17 cells than in our 5 controls of 17 -20 inflammatory active Crohn s disease. This lower percentage of Th17 in GvHD as compared to Crohn s disease should be kept in mind ' ' since this latter disease is usually considered as the prototypic Th1-Th17 GI disease . T cells numbers we detected in the GvHD 21 reg biopsies are in agreement with Rieger and coworkers study who found a mean of 5.4 cells/field and few T cells around crypts in acute 22 reg GvHD patients. It is of note however that, contrary to these authors, we did not found increased numbers of T in patients without GvHD. reg Today all our knowledge on the role of Th17 cells in GvHD comes from experimental mice studies that lead to divergent conclusions.
The role of Th17 has been studied in idiopathic pneumonia syndrome and chronic GvHD rodent models . Th17 was most recently 8 -9 studied in experimental acute GvHD. Carlson and coworkers reported that high dose of differentiated Th17 mediated severe 7 in vitro cutaneous and pulmonary lesions. Yi and coworkers showed that IL-17 / donor T cells had high Th1 differentiation and induced 11 − − severe acute GvHD damage. This is in accordance with the results of our human study, where a low Th17/T ratio also correlated with reg severe clinical and pathological GvHD, apoptosis intensity and TNF alpha expression. However, a limitation inherent to our human study design is that no sequential biopsies (i.e. in non symptomatic patients, early after transplantation) were performed. Thus recent experimental results of Kapple and coworkers and of Iclozan and colleagues suggesting that Th17 contributes to the early phase of 4 23
CD4-mediated GvHD cannot be ascertained in the present study. In another recent study Yi and coworkers used either wild-type mice 10 donor CD4 T cells that lead to a predominantly Th1 cell mediated disease that preferentially mediated GVHD tissue damage in the gut However we never found cells co-expressing IL-17 and Foxp3 in human biopsies.
Although this study represents the first one in human GvHD and is based on the analysis of nearly one hundred biopsies, we acknowledge some limitations. First larger number of patients with chronic GvHD should be studied. Second, a biopsy is only able to depict a situation (photography) at a given time post transplant even if this time correspond to early onset of clinical signs. Analyses we performed on these 2 cell subsets in peripheral blood found no correlation between Th17 cell percentage and GvHD occurrence and the Th17/Treg ratio was not statistically different between patients with or without signs of GvHD. Thus with the limitation inherent to human studies we cannot rule out that early pathogenetic mechanisms in human GvHD involve a prominent role of the Th17 cell subset. This is particularly relevant in view of recent results by Litjens and coworkers who demonstrated that the repertoire of alloreactive 27 in vitro CD4 T cells is biased to a Th17 response with an average 24 of alloreactive CD154 CD4 memory T cells producing IL-17 after
polyclonal stimulation. Unexpectedly, in this study mixed cell cultures from HLA-identical donors also generated alloreactive CD154 + CD4 T cells and yielded the highest frequency compared with HLA-non identical combinations.
+
In conclusion Th17 in human GvHD were not associated with evidence of severe tissue damage at disease onset, but in situ quantification of the Th17/T ratio was a specific marker of human GvHD. 
Footnotes:
Responsibilities GS designed the study and with PR and AJ analyzed the data and wrote the manuscript; CL and AD performed immunochemistry analyses; PB contributed to immunohistochemistry analyses; EC and CD collected and prepared PBMC; KK and RPL performed flow cytometry and analyzed data; CP and AQ collected and summarized clinical data; MR PR and RPL recruited patients and participated in manuscript discussion; JYM performed statistical analyses and actively participated to the writing of the manuscript.
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